Your browser doesn't support javascript.
loading
The Tumor Microenvironment of Clear-Cell Ovarian Cancer.
Devlin, Michael-John; Miller, Rowan; Laforets, Florian; Kotantaki, Panoraia; Garsed, Dale W; Kristeleit, Rebecca; Bowtell, David D; McDermott, Jacqueline; Maniati, Eleni; Balkwill, Frances R.
Afiliação
  • Devlin MJ; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Miller R; Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom.
  • Laforets F; Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom.
  • Kotantaki P; Department of Medical Oncology, University College London Hospital, London, United Kingdom.
  • Garsed DW; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Kristeleit R; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Bowtell DD; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • McDermott J; Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Maniati E; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Balkwill FR; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Cancer Immunol Res ; 10(11): 1326-1339, 2022 11 02.
Article em En | MEDLINE | ID: mdl-36095166
ABSTRACT
Some patients with advanced clear-cell ovarian cancer (CCOC) respond to immunotherapy; however, little is known about the tumor microenvironment (TME) of this relatively rare disease. Here, we describe a comprehensive quantitative and topographical analysis of biopsies from 45 patients, 9 with Federation Internationale des Gynaecologistes et Obstetristes (FIGO) stage I/II (early CCOC) and 36 with FIGO stage III/IV (advanced CCOC). We investigated 14 immune cell phenotype markers, PD-1 and ligands, and collagen structure and texture. We interrogated a microarray data set from a second cohort of 29 patients and compared the TMEs of ARID1A-wildtype (ARID1Awt) versus ARID1A-mutant (ARID1Amut) disease. We found significant variations in immune cell frequency and phenotype, checkpoint expression, and collagen matrix between the malignant cell area (MCA), leading edge (LE), and stroma. The MCA had the largest population of CD138+ plasma cells, the LE had more CD20+ B cells and T cells, whereas the stroma had more mast cells and αSMA+ fibroblasts. PD-L2 was expressed predominantly on malignant cells and was the dominant PD-1 ligand. Compared with early CCOC, advanced-stage disease had significantly more fibroblasts and a more complex collagen matrix, with microarray analysis indicating "TGFß remodeling of the extracellular matrix" as the most significantly enriched pathway. Data showed significant differences in immune cell populations, collagen matrix, and cytokine expression between ARID1Awt and ARID1Amut CCOC, which may reflect different paths of tumorigenesis and the relationship to endometriosis. Increased infiltration of CD8+ T cells within the MCA and CD4+ T cells at the LE and stroma significantly associated with decreased overall survival.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Microambiente Tumoral Limite: Female / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Microambiente Tumoral Limite: Female / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido